MarginsXMarginsX
Home › Markets › Health Care › BCDA

BioCardia Inc. (BCDA)

BCDA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.7901
-4.92% on the day
Market cap
$12.0M
Nano cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$8.2M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/925741/000143774926009587/0001437749-26-009587-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBCDA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000925741
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$8.2M
Operating income-$8.3M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$2.5M
Total assets$3.4M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
3.5 months
$2.2M cash at September 30, 2026
Share count, 1 year
+42.6%
2025-11-11 to 2026-11-11 · +950.4% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$169K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued."
10-Q 2026-11-12
Cash and burn$2.2M cash; operating cash flow -$1.9M a quarter.Report 2026-09-30
Shares outstanding15,138,782 (2026-11-11); 10,612,734 a year earlier; 21,619,432 three years earlier. 3y figure adjusted for splits (1-for-15 overall).Cover page 2026-11-11
Reverse splits, 3 years1; latest 1-for-15 on 2024-05-30Source 2024-05-30
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-08-21
AuditorPKF San Diego, LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $169K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$1.8M-$1.7M$2.2MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$1.6M-$1.7M$4.1MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2026
2026-03-31
Not filed-$2.3M-$1.7M$951KNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2025
2025-12-31
$0-$2.0M-$2.5M$2.5MNo debt tags$010-K 2026-03-24
Q3 2025
2025-09-30
$0-$1.5M-$1.7M$5.3MNo debt tags$010-Q 2025-11-12
Q2 2025
2025-06-30
$0-$2.0M-$1.6M$980KNo debt tags$010-Q/A 2025-10-29
Q1 2025
2025-03-31
$0-$2.7M-$1.6M$949KNo debt tags$3K10-Q 2025-05-14
Q4 2024
2024-12-31
$0-$2.3M-$2.4M$2.4MNo debt tags$58K10-K 2026-03-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM 424B5
424B52025-10-24
Latest annual report
FORM 10-K
10-K2026-03-24
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-12
Latest current report
FORM 8-K
8-K2026-11-12
Latest proxy
FORM DEF 14A
DEF 14A2025-11-03

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.4%
1 month-16.2%
3 months-10.8%
Year to date-33.6%
1 year-34.1%
From 52-week high-43.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
DYAIDyadic International Inc.$0.3200-2.14%$12.8M
JSPRJasper Therapeutics Inc.$11.77-13.96%$13.1M
PASGPassage Bio Inc.$4.13-2.82%$13.3M
ATYRaTyr Pharma Inc.$5.24-14.17%$13.4M
SCLXScilex Holding Company$1.25-12.59%$10.6M
ALGSAligos Therapeutics Inc.$1.66-20.95%$10.4M
INTSIntensity Therapeutics Inc.$3.07-0.32%$10.1M
PLURPluri Inc.$1.04-0.95%$15.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier